These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37790692)

  • 21. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.
    Maesaka K; Sakamori R; Yamada R; Doi A; Tahata Y; Miyazaki M; Ohkawa K; Mita E; Iio S; Nozaki Y; Yakushijin T; Imai Y; Kodama T; Hikita H; Tatsumi T; Takehara T
    Hepatol Res; 2022 Jul; 52(7):630-640. PubMed ID: 35417606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients.
    Toshida K; Itoh S; Tomiyama T; Morinaga A; Kosai Y; Tomino T; Kurihara T; Nagao Y; Morita K; Harada N; Yoshizumi T
    JGH Open; 2022 Jul; 6(7):477-486. PubMed ID: 35822124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
    Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
    Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
    Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
    Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials.
    Park R; Lopes da Silva L; Nissaisorakarn V; Riano I; Williamson S; Sun W; Saeed A
    J Hepatocell Carcinoma; 2021; 8():145-154. PubMed ID: 33791250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma.
    Cheon J; Kim H; Kim HS; Kim CG; Kim I; Kang B; Kim C; Jung S; Ha Y; Chon HJ
    Ther Adv Med Oncol; 2023; 15():17588359221148541. PubMed ID: 37705533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment.
    Kimura M; Yamada S; Go M; Yasuda S; Toyoda H; Usami E
    Oncol Lett; 2024 Jul; 28(1):330. PubMed ID: 38807665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
    Kosaka Y; Kawaoka T; Kosaka M; Shirane Y; Miura R; Murakami S; Johira Y; Yano S; Amioka K; Naruto K; Ando Y; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Aikata H
    Intern Med; 2023 Jun; 62(12):1771-1774. PubMed ID: 36328580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment.
    Chon YE; Cheon J; Kim H; Kang B; Ha Y; Kim DY; Hwang SG; Chon HJ; Kim BK
    Cancer Med; 2023 Feb; 12(3):2731-2738. PubMed ID: 35997637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.
    Cheon J; Yoo C; Hong JY; Kim HS; Lee DW; Lee MA; Kim JW; Kim I; Oh SB; Hwang JE; Chon HJ; Lim HY
    Liver Int; 2022 Mar; 42(3):674-681. PubMed ID: 34792284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis.
    Li S; Zhang Z; Wang Z; Wang K; Sui M; Liu D; Liang K
    Oncol Lett; 2024 Jun; 27(6):265. PubMed ID: 38659422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study.
    Huang X; Xu L; Ma T; Yin X; Huang Z; Ran Y; Ni Y; Bi X; Che X
    Front Oncol; 2021; 11():751159. PubMed ID: 34868952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Du S; Cao K; Wang Z; Lin D
    Medicine (Baltimore); 2023 Jun; 102(23):e33852. PubMed ID: 37335628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.